Cargando…

Fufang Zhenzhu Tiaozhi Capsule Prevents Intestinal Inflammation and Barrier Disruption in Mice With Non-Alcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) has become a major cause of liver transplantation and liver-associated death. Targeting the gut–liver axis is a potential therapy for NASH. The Fufang Zhenzhu Tiaozhi (FTZ) capsule, a traditional Chinese medicine commonly used in clinical practice, has recently em...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lan, Tian, Xu, Tonghao, Fu, Yanfang, Jiang, Shuo, Liang, Xiaolin, Yu, Ze, Pan, Linyu, Rong, Xianglu, Guo, Jiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243428/ https://www.ncbi.nlm.nih.gov/pubmed/35784533 http://dx.doi.org/10.3389/fendo.2022.864703

Ejemplares similares

Study on Metabolic Trajectory of Liver Aging and the Effect of Fufang Zhenzhu Tiaozhi on Aging Mice
por: Luo, Duosheng, et al.
Publicado: (2019)

Modulation of the Gut Microbiota by Fufang-Zhenzhu-Tiaozhi Capsule Attenuates Hypertension Induced by a High-Fructose and High-Salt Diet
por: Chen, Zhe, et al.
Publicado: (2022)

Traditional Chinese Medicine Fufang-Zhenzhu-Tiaozhi capsule prevents renal injury in diabetic minipigs with coronary heart disease
por: Song, Lixia, et al.
Publicado: (2022)

Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of NF-kappaB and inflammatory factors in rabbits
por: Zhang, Rendan, et al.
Publicado: (2018)

Analysis of the Constituents in Rat Serum after Oral Administration of Fufang Zhenzhu Tiaozhi Capsule by UPLC–Q–TOF–MS/MS
por: Zhong, Xunlong, et al.
Publicado: (2011)

The Efficacy and Safety of Chinese Medicine Fufang Zhenzhu Tiaozhi Capsule (FTZ) in the Treatment of Diabetic Coronary Heart Disease: Study Protocol for Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Wang, Lexun, et al.
Publicado: (2021)

Long-Term Effect of Zhenzhu Tiaozhi Capsule (FTZ) on Hyperlipidemia: 2-Year Results from a Retrospective Study Using Electronic Medical Records
por: Huang, Xiaoqiang, et al.
Publicado: (2021)

Untargeted Metabolomics Reveals the Protective Effect of Fufang Zhenshu Tiaozhi (FTZ) on Aging-Induced Osteoporosis in Mice
por: Luo, Duosheng, et al.
Publicado: (2019)

The Target MicroRNAs and Potential Underlying Mechanisms of Yiqi-Bushen-Tiaozhi Recipe against‐Non-Alcoholic Steatohepatitis
por: Hong, Wei, et al.
Publicado: (2020)

Exploring the Regulation of Jiangtang Tiaozhi Formula on the Biological Network of Obese T2DM Complicated With Dyslipidemia Based on Clinical Transcriptomics
por: Bao, Tingting, et al.
Publicado: (2022)

The therapeutic effect of Fufang Zhenshu Tiaozhi (FTZ) on osteoclastogenesis and ovariectomized-induced bone loss: evidence from network pharmacology, molecular docking and experimental validation
por: Chen, Xiaojun, et al.
Publicado: (2022)

Network pharmacology analysis and experimental validation to explore the mechanism of Bushao Tiaozhi capsule (BSTZC) on hyperlipidemia
por: Xiao, Guanlin, et al.
Publicado: (2022)

Deciphering the mechanisms of Yinlan Tiaozhi capsule in treating hyperlipidemia by combining network pharmacology, molecular docking and experimental verification
por: Xiao, Guanlin, et al.
Publicado: (2023)

Metabolomics analysis delineates the therapeutic effects of Yinlan Tiaozhi capsule on triton WR-1339 -induced hyperlipidemia in mice
por: Xiao, Guanlin, et al.
Publicado: (2023)

Chinese medicinal formula Fufang Xueshuantong capsule could inhibit the activity of angiotensin converting enzyme
por: Sheng, Shujing, et al.
Publicado: (2014)

Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies
por: Luci, Carmelo, et al.
Publicado: (2020)

Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway
por: Liu, Yu, et al.
Publicado: (2021)

Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
por: Lan, Tian, et al.
Publicado: (2021)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Yiqi-Bushen-Tiaozhi Recipe Attenuated High-Fat and High-Fructose Diet Induced Nonalcoholic Steatohepatitis in Mice via Gut Microbiota
por: Yan, Junbin, et al.
Publicado: (2022)

Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling
por: Pan, Linyu, et al.
Publicado: (2023)

Effects of Tiaozhi Granule on Regulation of Autophagy Levels in HUVECs
por: Wu, Ying-Ying, et al.
Publicado: (2018)

FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
por: Tillman, Erik J., et al.
Publicado: (2020)

Fufang Xue Shuan Tong capsules inhibit renal oxidative stress markers and indices of nephropathy in diabetic rats
por: FANG, DONGHONG, et al.
Publicado: (2012)

Correlations Between MRI Biomarkers PDFF and cT1 With Histopathological Features of Non-Alcoholic Steatohepatitis
por: Dennis, Andrea, et al.
Publicado: (2021)

Transcriptomic changes in liver transplant recipients with non-alcoholic steatohepatitis indicate dysregulation of wound healing
por: Pellegrina, Diogo, et al.
Publicado: (2023)

Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
por: Mouries, Juliette, et al.
Publicado: (2019)

Interventional Potential of Recombinant Feline Hepatocyte Growth Factor in a Mouse Model of Non-alcoholic Steatohepatitis
por: Yang, Yoon Mee, et al.
Publicado: (2018)

Proteomics and network pharmacology of Ganshu Nuodan capsules in the prevention of alcoholic liver disease
por: Yang, Xiaonan, et al.
Publicado: (2023)

Investigation into the potential mechanism and molecular targets of Fufang Xueshuantong capsule for the treatment of ischemic stroke based on network pharmacology and molecular docking
por: Wang, Lei, et al.
Publicado: (2022)

Efficacy and safety of Fufang Xueshuantong Capsules in combination with conventional drugs in the treatment of glaucoma: A meta-analysis and trial sequential analysis
por: Zeng, Zhicheng, et al.
Publicado: (2023)

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis
por: Hwang, Seonghwan, et al.
Publicado: (2021)

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
por: Xiang, Hui, et al.
Publicado: (2022)

Gynostemma pentaphyllum polysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway
por: Yue, Si-Ran, et al.
Publicado: (2022)

Protective Effects of Fufang Xueshuantong on Diabetic Retinopathy in Rats
por: Duan, Huihui, et al.
Publicado: (2013)

Antioxidant and Immunity Activities of Fufang Kushen Injection Liquid
por: Zhou, Shen-Kang, et al.
Publicado: (2012)

Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence
por: Yabiku, Koichi
Publicado: (2021)

Integrative network-based analysis on multiple Gene Expression Omnibus datasets identifies novel immune molecular markers implicated in non-alcoholic steatohepatitis
por: Zhang, Jun-jie, et al.
Publicado: (2023)

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
por: Kim, Kook Hwan, et al.
Publicado: (2018)

Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ok6fdf6l672v6t2t571qerprta